Nautilus Biotechnology Inc., founded in 2016, is developing a proteomics platform designed to analyze the human proteome with greater sensitivity and scale than previously possible. The company's core technology integrates hyper-dense single-molecule arrays, multi-affinity probes, and machine learning. The Nautilus Proteome Analysis Platform uses arrays containing billions of 'landing pads' to isolate individual proteins, which are then probed iteratively with multi-affinity probes. Machine learning algorithms are applied to interpret the resulting binding patterns.
The platform aims to identify and quantify up to 95% of the human proteome. This represents a significant advance over traditional proteomics methods, which could measure approximately 30% of the proteome. The company's work spans the technical domains of proteomics, machine learning, single-molecule arrays, and multi-affinity probe design.
Nautilus Biotechnology's platform has applications across drug development, diagnostics, and personalized medicine. The company was founded on the recognition of existing technological limitations in proteomics and the pursuit of a substantial scientific advancement in the field.
